Abstract:The successful treatment of hematologic malignances with allogeneic hematopoietic cell transplantation (allo-HCT) is limited by acute graft-versus-host disease (GvHD). The complement system has been shown to modulate adaptive immunity via interaction between complement activation products and their receptors expressed on both innate and adaptive immune cells. Complement receptors play an important role in pathogen and danger sensing by translating information gathered by complement fluid phase sensors into cellular responses. The anaphylatoxins, C3a and C5a, are key effector molecules of the complement system. C3aR/C5aR signaling plays an important role in the survival, maturation and differentiation of antigen presenting cells (APCs), as well as for effective antigen presentation to T cells and the subsequent modulation of T-cell proliferation, differentiation and function. Given that host APCs play a crucial role in priming alloreactive donor T cells to induce and intensify aGvHD, we evaluated the role of C3aR/C5aR in the induction of aGvHD via the regulation of host APC function. Using the two distinct well-defined, clinically relevant aGVHD models, B6 (H2 b )-u003eBALB/c (H2 d ) and FVB (H2 q )-u003eB6 (H2 b ), we observed that host C3aR/5aR deficiency led to a significantly reduced aGvHD as indicated by a higher survival rate and milder GvHD clinical scores as compared to WT recipients ( Figure 1A ). The ameliorated GVHD in C3aR/C5aR -/- recipients was associated with reduced donor T-cell activation, survival, bioenergetic capacity and Th1 differentiation, and with increased iTreg generation. Donor T cells in C3aR/C5aR -/- recipients express lower levels of chemokine receptors, CXCR3 and CCR6, which is likely responsible for the decreased migration of the effector T cells to GvHD target organs. Utilizing BM chimeras to distinguish the role of C3aR/C5aR on host hematopoietic cells vs. parenchymal tissues in the development of GVHD, we found that C3aR/C5aR expressed on recipient hematopoietic APCs was primarily responsible for donor T-cell response and pathogenicity in aGvHD. Among APCs, DCs are considered to be the most efficacious APCs due to their superior ability to take up antigen, express co-stimulatory molecules, and produce pro-inflammatory cytokines to polarize alloreactive T cells. C3aR/C5aR expression was drastically upregulated in DCs after total body irradiation. In comparison with WT DCs, irradiated C3aR/C5aR -/- DCs displayed higher apoptosis which is associated with DC upregulation of Fas expression, higher autophagy, and decreased activation and antigen presenting capacity reflected by lower IFN-γ positive DC cells and reduced MHCII expression. Notably, while C3aR/C5aR on hematopoietic cells was required for GVHD development, it was largely dispensable for the graft-versus-leukemia (GVL) effect. For translational application, we evaluated the effect of systemic administration of a combination of C3aR and C5aR antagonists (C3aRA/C5aRA) to block C3aR/C5aR signaling, on GVHD and GVL activity. We found that prophylactic treatment of recipients with C3aRA/C5aRA prior to transplant effectively prevented GvHD while preserving GVL effect ( Figure 1B ). Taken together, the current work provides a strong rationale and demonstrates the feasibility to target host C3aR/C5aR for the control of GVHD while preserving GVL activity after allo-HCT. Disclosures No relevant conflicts of interest to declare.

The Synthetic Triterpenoid, CDDO, Suppresses Alloreactive T Cell Responses and Reduces Murine Early Acute Graft-Versus-host Disease Mortality.

The Triterpenoid CDDO-Me Delays Murine Acute Graft-Versus-host Disease with the Preservation of Graft-Versus-tumor Effects after Allogeneic Bone Marrow Transplantation.

A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.

Down Regulation Of Cxc Chemokine Receptor 3 Impedes The Ability Of Anti-Cxcr3 Antibody To Block Graft-Versus-Host Disease

HIF-1α Inhibitor Echinomycin Reduces Acute Graft-Versus-host Disease and Preserves Graft-Versus-leukemia Effect

Modulating the Conformation of the TIR Domain by a Neoteric MyD88 Inhibitor Leads to the Separation of GVHD from GVT.

CXCR3 Blockade Combined with Cyclosporine A Alleviates Acute Graft-Versus-host Disease by Inhibiting Alloreactive Donor T Cell Responses in a Murine Model

[Experimental Study of Tripterygium Hypoglaucum (level) Hutch on Preventing Acute Graft-Versus-host Disease in Bone Marrow Transplantation Mice].

Inhibition of Acute Graft-versus-Host Disease with Retention of Graft-versus-Tumor Effects by Dimethyl Fumarate.

Targeting the Retinoid X Receptor Pathway Prevents and Ameliorates Murine Chronic Graft-Versus-Host Disease

TAK1 inhibition ameliorates survival from graft-versus-host disease in an allogeneic murine marrow transplantation model

Vitamin D-modulated dendritic cells delay lethal graft-versus-host disease through induction of regulatory T cells

Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response

Blockade of CCR5 and CXCR3 Attenuates Murine Acute Graft-Versus-host Disease Through Modulating Donor-Derived T Cell Distribution and Function

Prevention of murine acute graft-versus-host disease by recipient-derived TGFbeta1-treated dendritic cells

Prophylaxis of acute graft-versus-host disease by CCR5 blockade combined with cyclosporine A in a murine model

Targeting Host Complement C3a/C5a Receptors To Control Of Acute Graft-Versus-Host Disease In Mice

Combined Ccr5 And Cxcr3 Blockade Attenuates Murine Agvhd Through Alternating Donor-Derived T Cell Distribution And Function

Complement C3a and C5a Receptors Promote GVHD by Suppressing Mitophagy in Recipient Dendritic Cells.

Role of Defibrotide in the Prevention of Murine Model Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

High-dose Alemtuzumab-Cyclosporine vs Tacrolimus-Methotrexate-Sirolimus for Chronic Graft-versus-Host Disease Prevention